These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25602127)

  • 1. Adrenal reserve following treatment of Graves' orbitopathy with intravenous glucocorticoids.
    Giotaki Z; Fountas A; Tsirouki T; Bargiota A; Tigas S; Tsatsoulis A
    Thyroid; 2015 Apr; 25(4):462-3. PubMed ID: 25602127
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of Graves' orbitopathy treatment with intravenous glucocorticoids on adrenal function.
    Ambroziak U; Bluszcz G; Bednarczuk T; Miśkiewicz P
    Endokrynol Pol; 2017; 68(4):430-433. PubMed ID: 28604944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test.
    Pelewicz K; Miśkiewicz P
    J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of combined parenteral and oral steroid therapy in Graves' orbitopathy.
    Nedeljkovic Beleslin B; Ciric J; Zarkovic M; Stojkovic M; Savic S; Knezevic M; Stankovic B; Trbojevic B
    Hormones (Athens); 2014; 13(2):222-8. PubMed ID: 24776622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylprednisolone-induced liver injury: a diagnostic challenge.
    Melamud B; Lurie Y; Goldin E; Levi I; Esayag Y
    Isr Med Assoc J; 2014 Mar; 16(3):180-1. PubMed ID: 24761710
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
    Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
    Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
    Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
    J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of systemic steroid therapy in Graves' orbitopathy on regulatory T cells and Th17/Treg ratio.
    Siomkajło M; Mizera Ł; Szymczak D; Kolačkov K; Grzegrzółka J; Bolanowski M; Daroszewski J
    J Endocrinol Invest; 2021 Nov; 44(11):2475-2484. PubMed ID: 33866536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myocardial infarction during high-dose methylprednisolone therapy for Graves' ophthalmopathy.
    Owecki M; Sowiński J
    Pharm World Sci; 2006 Apr; 28(2):73-5. PubMed ID: 16791713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
    Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of methylprednisolone pulse therapy for Graves' ophthalmopathy.
    Gao G; Dai J; Qian Y; Ma F
    Clin Exp Ophthalmol; 2014 Nov; 42(8):769-77. PubMed ID: 24617953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail?
    Bartalena L
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):149-52. PubMed ID: 20148907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of digital infrared thermal imaging in determining inflammatory state and follow-up effect of methylprednisolone pulse therapy in patients with Graves' ophthalmopathy.
    Chang TC; Hsiao YL; Liao SL
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):45-9. PubMed ID: 17653750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.
    Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Vitti P; Marcocci C; Brunetto M; Marinò M
    Thyroid; 2015 Jul; 25(7):846-50. PubMed ID: 26090805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
    Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
    Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions.
    Campi I; Currò N; Vannucchi G; Covelli D; Simonetta S; Fugazzola L; Dazzi D; Pignataro L; Guastella C; Lazzaroni E; Pirola G; Salvi M
    Thyroid; 2021 Feb; 31(2):280-287. PubMed ID: 32940167
    [No Abstract]   [Full Text] [Related]  

  • 17. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
    Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
    Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.
    Riedl M; Kolbe E; Kampmann E; Krämer I; Kahaly GJ
    J Endocrinol Invest; 2015 Feb; 38(2):177-82. PubMed ID: 25576458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
    Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
    Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.